ClinicalTrials.gg
Not yet recruitingNCT07861152EMERGEUpdated Oct 6, 2026

Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)

A Phase 1 interventional study of REGN24493 and Placebo in Graves' Disease, sponsored by Regeneron Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will test an experimental Regeneron drug called REGN24493 hereby referred to as "study drug" to see if it can help treat Graves' disease. Graves' disease is a condition where the immune system causes the thyroid gland to make too much thyroid hormone.

The main purpose of this study is to learn about the safety of REGN24493 and what side effects it might cause.

The study is looking at:

  • What side effects REGN24493 might cause
  • How much REGN24493 is in the blood at different times
  • How REGN24493 affects thyroid hormone levels
  • If the body reacts to REGN24493 in a way that could affect participant's health
  • What is the best dose of REGN24493 for treating Graves' disease
02

Conditions studied

  • Graves' Disease

Browse trials for

Keywords

  • Autoimmune hyperthyroidism
  • Autoimmune thyroid disease
  • Graves' disease
  • Graves' hyperthyroidism
  • Thyroid stimulating hormone receptor
  • Thyroid stimulating immunoglobulin (TSI)
  • TRAb (TSH receptor antibody)
  • TSHR
  • TSHR autoantibody
03

In context

Graves Disease

162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.

This study's planned enrollment of 45 is below the median of 60 across 104 interventional studies indexed under Graves Disease.

Browse Graves Disease studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has a diagnosis of Graves' Disease for at least 4 months prior to the screening visit
  2. Has thyroid-stimulating hormone receptor antibody (TRAb) level above the at the screening visit
  3. Euthyroid at the screening visit and at least 4 weeks prior to the screening visit as defined in the protocol
  4. (BMI) between 18.5 and 35.0 kg/m\^2 (inclusive) at the screen visit

Key Exclusion Criteria:

  1. Has history of hyperthyroidism not caused by Graves' disease (eg, toxic thyroid adenoma, multinodular goiter, amiodarone-induced)
  2. Has active thyroid storm or is at current risk of thyroid storm, as assessed by the investigator at the screening visit
  3. Has cardiac abnormalities attributable to uncontrolled Graves' disease (eg, arrhythmias precipitated by thyrotoxicosis, thyrotoxic cardiomyopathy)
  4. Has any infection requiring systemic therapy within the 4 weeks prior to the screening visit
  5. Was hospitalized (ie, >24 hours) for a reason within 30 days of the screening visit that presents any concern to the trial investigator
  6. Has used or is using Levothyroxine (LT4) therapy at any dose within 6 weeks of the screening visit
  7. Has history of Radioactive iodine (RAI) thyroid ablation or thyroidectomy

Note: Other protocol defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Drug: REGN24493

  • Placebo comparator
    Placebo Comparator

    Drug: Placebo

Interventions

  • DrugREGN24493

    Administered per the protocol.

  • DrugPlacebo

    Administered per the protocol.

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 68 weeks

Secondary outcomes

  1. Concentrations of REGN24493 in serum

    Time frame: Day 1 through Week 68

  2. Serum Thyroid-Stimulating Hormone (TSH) levels

    Time frame: Day 1 through Week 68

  3. Serum free T4 (fT4) levels

    Time frame: Day 1 through Week 68

  4. Serum free T3 (fT3) levels

    Time frame: Day 1 through Week 68

  5. Serum total T3 (TT3) levels

    Time frame: Day 1 through Week 68

  6. Occurrence of anti-drug antibody (ADA) to REGN24493 in serum

    Time frame: Day 1 through Week 68

  7. Magnitude of anti-drug antibody (ADA) to REGN24493 in serum

    Time frame: Day 1 through Week 68

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2030, 38 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Nov 2, 2026
Primary completionEst.
Jan 28, 2030
CompletionEst.
Jan 28, 2030
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861152
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Nov 2, 2026 (estimated)
Primary completion
Jan 28, 2030 (estimated)
Completion
Jan 28, 2030 (estimated)
Last update
Oct 6, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion